According to the latest report by IMARC Group, titled North America Hormone Replacement (HRT) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025, the hormone replacement market in North America reached a value of US$ 502.6 Million in 2019. Hormone replacement therapy (HRT) is the most effective treatment that is used to supplement the hormones present in low levels in the human body. This treatment is usually suggested for patients who are experiencing growth hormone deficiency, women nearing menopause and elderly who are suffering from hypogonadism. Continue reading →

Prophecy Market Insights Hormone Replacement Therapy market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges during COVID-19 pandemic across the globe. Hormone Replacement Therapy Devices Market reports provide in-depth analysis of Top Players, Geography, End users, Applications, Competitor analysis, Revenue, Financial Analysis, Market Share, COVID-19 Analysis, Trends and Forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses Continue reading →

ROCKLAND, Mass. and NEW YORK, June 30, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy Continue reading →

It began around the time she turned 47. All of a sudden, Layla Singam felt like her body was out of her control. She was exercising four times a week and eating sensibly as shed been doing for years but she was gaining weight. Continue reading →

Alexion Pharma Receives European Approval for Ultomiris Alexion Pharmaceuticals (ALXN) announced that its lead drug candidate Ultomiris has been approved by the European Commission. Ultomiris may now be used for treating adults and children with atypical hemolytic uremic syndrome in Europe Continue reading →

IT is something every woman goes through but the menopause is still shrouded in stigma. Continue reading →